In the ongoing battle against antibiotic resistance, a new study published in Engineering by Zhuoren Ling’s research team unveils a promising triple combination of antibiotics that significantly ...

Titled "The Triple Combination of Meropenem, Avibactam, and a Metallo-β-Lactamase Inhibitor Optimizes Antibacterial Coverage Against Different β-Lactamase Producers," the research sheds light on a ...

EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by ...

Carbapenem-resistant Enterobacterales species and multidrug-resistant Pseudomonas aeruginosa are global health threats. Cefepime–taniborbactam is an investigational β-lactam and β-lactamase inhibitor ...

Panelists discuss how sulopenem etzadroxil/probenecid, approved in October 2024, functions as an oral β-lactam/β-lactamase inhibitor effective against extended-spectrum β-lactamase producers per SURE ...

Chengdu Tetrahedral Drug Research Co. Ltd. has synthesized bicyclic derivatives acting as β-lactamase (bacterial) inhibitors reported to be useful for the treatment of bacterial infection.

PALO ALTO, Calif.--(BUSINESS WIRE)--Arixa Pharmaceuticals™, Inc., a company dedicated to developing next-generation oral antibiotics for drug-resistant Gram-negative infections today announced that ...

Exblifep is a combination product that consists of cefepime, a cephalosporin antibacterial, and enmetazobactam, a beta-lactamase inhibitor. The Food and Drug Administration (FDA) has approved Exblifep ...

The FDA has approved aztreonam and avibactam (Emblaveo) in combination with metronidazole for adults who have limited or no alternative options for the treatment of complicated intra-abdominal ...